Literature DB >> 12421588

Development of Vero cell-derived inactivated Japanese encephalitis vaccine.

Keishin Sugawara1, Kiyoto Nishiyama, Yuji Ishikawa, Motoharu Abe, Kengo Sonoda, Kazuhiro Komatsu, Yoshikane Horikawa, Kengo Takeda, Tomitaka Honda, Shoji Kuzuhara, Yoichiro Kino, Hiroshi Mizokami, Kyosuke Mizuno, Tetsuya Oka, Kennosuke Honda.   

Abstract

We have established a manufacturing system for a Vero cell-derived inactivated Japanese encephalitis vaccine at a 500l scale. The production system involves expansion of Vero cells using microcarrier, followed by virus infection. Except for an additional purification step, the downstream purification processes are similar to those used for the current mouse brain-derived vaccine; cell removal, concentration and removal of low-molecular weight impurities by membrane filtration, formalin-inactivation, sucrose density gradient ultracentrifugation, and Sulfate-Cellulofine column chromatography are conducted. The antigen obtained from the manufacturing system was highly purified and its physico-chemical and immunological properties were comparable with those of antigen derived from mouse brains. Our system is very simple and could be easily scaled-up to allow vaccine production at a several thousand litre scale. Copyright 2002 The International Association for Biologicals. Published by Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421588     DOI: 10.1006/biol.2002.0345

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  17 in total

1.  Enhanced growth of influenza vaccine seed viruses in vero cells mediated by broadening the optimal pH range for virus membrane fusion.

Authors:  Shin Murakami; Taisuke Horimoto; Mutsumi Ito; Ryo Takano; Hiroaki Katsura; Masayuki Shimojima; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

2.  Enhanced growth of seed viruses for H5N1 influenza vaccines.

Authors:  Taisuke Horimoto; Shin Murakami; Yukiko Muramoto; Shinya Yamada; Ken Fujii; Maki Kiso; Kiyoko Iwatsuki-Horimoto; Yoichiro Kino; Yoshihiro Kawaoka
Journal:  Virology       Date:  2007-07-24       Impact factor: 3.616

3.  The effects of microcarrier culture on recombinant CHO cells under biphasic hypothermic culture conditions.

Authors:  Jong Hyun Nam; Myriam Ermonval; Susan T Sharfstein
Journal:  Cytotechnology       Date:  2009-05-02       Impact factor: 2.058

4.  Phase III clinical trials comparing the immunogenicity and safety of the vero cell-derived Japanese encephalitis vaccine Encevac with those of mouse brain-derived vaccine by using the Beijing-1 strain.

Authors:  Chiaki Miyazaki; Kenji Okada; Takao Ozaki; Mizuo Hirose; Kaneshige Iribe; Hiroyuki Yokote; Yuji Ishikawa; Takehiro Togashi; Kohji Ueda
Journal:  Clin Vaccine Immunol       Date:  2013-12-11

5.  An improved reverse genetics system for influenza A virus generation and its implications for vaccine production.

Authors:  Gabriele Neumann; Ken Fujii; Yoichiro Kino; Yoshihiro Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-02       Impact factor: 11.205

Review 6.  Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.

Authors:  Nagendra R Hegde; Milind M Gore
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

7.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

8.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.

Authors:  Mario Lobigs; Megan Pavy; Roy A Hall; Päivi Lobigs; Peter Cooper; Tomoyoshi Komiya; Hiroko Toriniwa; Nikolai Petrovsky
Journal:  J Gen Virol       Date:  2010-02-03       Impact factor: 3.891

Review 9.  Japanese encephalitis and vaccines: past and future prospects.

Authors:  Maria Paulke-Korinek; Herwig Kollaritsch
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

10.  Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO].

Authors:  Sean T Duggan; Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.